Lawrence T.  Weiss net worth and biography

Lawrence Weiss Biography and Net Worth

Larry Weiss was appointed Senior Vice President, Chief Legal Officer, and Corporate Secretary in December 2024.

Before joining AngioDynamics, Larry was Executive Vice President and Chief Legal Officer of Butterfly Network, Inc., overseeing legal, compliance, quality, and regulatory functions. Prior roles include Chief Legal Officer of Emulate, Inc., and Senior Vice President, General Counsel, and Corporate Secretary for Analog Devices, Inc., where he led legal strategy and compliance for a global semiconductor business.

Larry’s career includes leadership positions at Medtronic, Covidien, and Tyco Healthcare, where he managed international legal matters, mergers and acquisitions, intellectual property litigation, and global compliance initiatives. He began his career in the Corporate department of Goodwin Procter & Hoar in Boston.

Larry holds a Juris Doctor from Boston University and a Bachelor’s degree from Tulane University. He serves on the Boards of Directors for Greater Boston Legal Services and the Northeast Chapter of the Association for Corporate Counsel.

What is Lawrence T. Weiss' net worth?

The estimated net worth of Lawrence T. Weiss is at least $1.05 million as of October 21st, 2025. Weiss owns 93,597 shares of AngioDynamics stock worth more than $1,054,838 as of March 25th. This net worth approximation does not reflect any other investments that Weiss may own. Learn More about Lawrence T. Weiss' net worth.

How do I contact Lawrence T. Weiss?

The corporate mailing address for Weiss and other AngioDynamics executives is 14 PLAZA DRIVE, LATHAM NY, 12110. AngioDynamics can also be reached via phone at (518) 795-1400 and via email at [email protected]. Learn More on Lawrence T. Weiss' contact information.

Has Lawrence T. Weiss been buying or selling shares of AngioDynamics?

Lawrence T. Weiss has not been actively trading shares of AngioDynamics within the last three months. Most recently, on Tuesday, October 21st, Lawrence T. Weiss bought 10,000 shares of AngioDynamics stock. The stock was acquired at an average cost of $11.81 per share, with a total value of $118,100.00. Following the completion of the transaction, the senior vice president now directly owns 93,597 shares of the company's stock, valued at $1,105,380.57. Learn More on Lawrence T. Weiss' trading history.

Who are AngioDynamics' active insiders?

AngioDynamics' insider roster includes Chad Campbell (SVP), Scott Centea (VP), James Clemmer (CEO), James Clemmer (CEO), Dave Helsel (SVP), Warren Jr (SVP), Stephen Trowbridge (CFO), and Lawrence Weiss (SVP). Learn More on AngioDynamics' active insiders.

Are insiders buying or selling shares of AngioDynamics?

During the last twelve months, AngioDynamics insiders bought shares 3 times. They purchased a total of 20,890 shares worth more than $239,532.40. The most recent insider tranaction occured on October, 21st when SVP Lawrence T Weiss bought 10,000 shares worth more than $118,100.00. Insiders at AngioDynamics own 6.0% of the company. Learn More about insider trades at AngioDynamics.

Information on this page was last updated on 10/21/2025.

Lawrence T. Weiss Insider Trading History at AngioDynamics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/21/2025Buy10,000$11.81$118,100.0093,597View SEC Filing Icon  
See Full Table

Lawrence T. Weiss Buying and Selling Activity at AngioDynamics

This chart shows Lawrence T Weiss's buying and selling at AngioDynamics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AngioDynamics Company Overview

AngioDynamics logo
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
Read More

Today's Range

Now: $11.20
Low: $10.74
High: $11.30

50 Day Range

MA: $10.77
Low: $9.98
High: $11.46

2 Week Range

Now: $11.20
Low: $8.36
High: $13.99

Volume

299,953 shs

Average Volume

552,764 shs

Market Capitalization

$461.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48